Inhibits activation and mediator release from sensitised mast cells and other inflammatory cells. The precise molecular mechanism is not fully established; it acts prophylactically and is not a rapid bronchodilator. Sodium cromoglicate is a salt of the same active moiety.
Indications / reported uses
Prevention of bronchial asthma symptoms with inhaled formulations
Treatment or prevention of allergic rhinitis with nasal formulations
Relief of allergic conjunctivitis with ophthalmic formulations
Selected systemic use for mastocytosis with oral formulations; use is route- and product-specific
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Cromoglicate Environmental Risk Assessment (ERA) (the Cromoglicate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.